Compounds > kalata b2
Page last updated: 2024-11-13

kalata b2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

kalata B2: conformation in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID56669818
CHEMBL ID1801137
MeSH IDM0561364

Synonyms (2)

Synonym
kalata b2
CHEMBL1801137
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID605689Insecticidal activity against Helicoverpa armigera assessed as growth inhibition2010Journal of natural products, Sep-24, Volume: 73, Issue:9
Isolation, sequencing, and structure-activity relationships of cyclotides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (33.33)29.6817
2010's6 (66.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.27 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phosphorylethanolamine
phosphorylethanolamine: RN given refers to parent cpd; structure. O-phosphoethanolamine : The ethanolamine mono-ester of phosphoric acid, and a metabolite of phospholipid metabolism. This phosphomonoester shows strong structural similarity to the inhibitory neurotransmitter GABA, and is decreased in post-mortem Alzheimer's disease brain.		2.0710phosphoethanolamine;
primary amino compound		algal metabolite;
human metabolite;
mouse metabolite
goethite
[no description available]		7.0610
kalata b1
kalata B1: a 29-residue cyclotide which has a cystine knot structure and beta-sheet; causes uterine contraction; the principal active component from Oldenlandia affinis; amino acid sequence given in first source		4.5570
cycloviolacin o13
cycloviolacin O13: amino acid sequence in first source		3.1510
cycloviolacin o2
cycloviolacin O2: macrocyclic peptide (cyclotide) from the two violets, Viola arvensis Murr. and Viola odorata (Violaceae); amino acid sequence in first source		2.4820
ConditionIndicatedRelationship StrengthStudiesTrials